I agree GAC ... in terms of excitement, energy, confidence in the future ... BT status would be nearly like TLD/FLD success at this point, in a number of manners. A "clear path to commercialization" with limited indications probably, and a P4 to further validate, and to potentially add indications and broader usage applicability?

It would be huge news for both investors and potential partners/buyers ... to a BP, just imagine the differences in viewpoint and valuation regarding apabetalone if BT status occurs, rather than another 3-4 year P3 that shows promise but is presently deemed viewed as unproven to be of benefit to patients, along with the costs and patent-life depleting time involved?

I believe (hope?) we have a real shot at BT status, given the safety profile, narrow miss on BoM, and select data in the sub-studies with excellent "p" values in areas of unmet need and VERY high financial burdens ... and given the regulatory statements about their transcendent approval goals and environment for unmet needs.

It all adds up logically to a decent shot at BT status imho ... however, the decisions are ultimately made by humans and not an algorithm ... so there's that :)